Profile data is unavailable for this security.
About the company
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
- Revenue in USD (TTM)0.00
- Net income in USD-199.06m
- Incorporated2000
- Employees251.00
- LocationXenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
- Phone+1 (604) 484-3300
- Fax+1 (604) 484-3450
- Websitehttps://www.xenon-pharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Veracyte Inc | 399.58m | -54.04m | 2.53bn | 815.00 | -- | 2.23 | -- | 6.34 | -0.7444 | -0.7444 | 5.37 | 14.76 | 0.3336 | 8.11 | 8.62 | 490,281.00 | -4.51 | -6.33 | -4.77 | -6.69 | 68.73 | 67.10 | -13.52 | -20.99 | 4.17 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
Geron Corp | 1.37m | -219.55m | 2.60bn | 141.00 | -- | 8.45 | -- | 1,892.24 | -0.3595 | -0.3595 | 0.0023 | 0.5103 | 0.0032 | -- | 0.6367 | 9,737.59 | -50.78 | -51.32 | -63.77 | -64.90 | 63.00 | -- | -15,990.60 | -19,949.13 | 3.60 | -- | 0.2139 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Protagonist Therapeutics Inc | 319.12m | 169.95m | 2.61bn | 125.00 | 16.81 | 4.81 | 15.28 | 8.18 | 2.64 | 2.64 | 5.22 | 9.21 | 0.6825 | -- | 449.46 | 2,849,286.00 | 36.35 | -35.90 | 39.20 | -41.36 | -- | -- | 53.26 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Guardant Health Inc | 643.81m | -490.76m | 2.68bn | 1.78k | -- | -- | -- | 4.17 | -4.09 | -4.09 | 5.36 | -0.0131 | 0.3733 | 4.04 | 6.89 | 361,894.30 | -28.46 | -22.26 | -32.21 | -24.59 | 59.95 | 64.62 | -76.23 | -97.07 | 6.07 | -10.18 | 1.00 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
PTC Therapeutics, Inc. | 900.45m | -479.52m | 2.72bn | 988.00 | -- | -- | -- | 3.02 | -6.32 | -6.32 | 11.84 | -12.75 | 0.5534 | 2.16 | 4.94 | 911,390.70 | -29.47 | -26.71 | -44.23 | -33.46 | 92.35 | 93.94 | -53.25 | -83.80 | 2.17 | -1.16 | 1.70 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Kymera Therapeutics Inc | 88.55m | -157.85m | 2.80bn | 181.00 | -- | 3.90 | -- | 31.57 | -2.41 | -2.41 | 1.36 | 11.12 | 0.1258 | -- | 30.40 | 473,529.40 | -22.42 | -23.03 | -24.45 | -27.64 | -- | -- | -178.27 | -207.82 | -- | -- | 0.0028 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Iovance Biotherapeutics Inc | 32.77m | -440.22m | 2.96bn | 557.00 | -- | 3.78 | -- | 90.39 | -1.68 | -1.68 | 0.1245 | 2.59 | 0.0381 | 2.40 | 2.07 | 58,836.63 | -51.14 | -51.47 | -57.20 | -57.56 | -37.43 | -- | -1,343.27 | -137,873.80 | 4.85 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Rhythm Pharmaceuticals Inc | 101.78m | -260.73m | 2.97bn | 226.00 | -- | 75.44 | -- | 29.18 | -4.37 | -4.37 | 1.71 | 2.94 | 0.2943 | 1.25 | 6.48 | 450,367.30 | -75.00 | -47.21 | -87.80 | -52.84 | 88.80 | -- | -254.88 | -681.38 | 6.31 | -- | 0.3765 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Xenon Pharmaceuticals Inc | 0.00 | -199.06m | 3.01bn | 251.00 | -- | 3.56 | -- | -- | -2.74 | -2.74 | 0.00 | 11.15 | 0.00 | -- | -- | 0.00 | -25.38 | -20.71 | -26.37 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Amicus Therapeutics, Inc. | 455.66m | -119.54m | 3.13bn | 517.00 | -- | 23.62 | -- | 6.87 | -0.397 | -0.397 | 1.51 | 0.4471 | 0.6159 | 0.6948 | 6.12 | 881,344.30 | -16.16 | -30.65 | -20.75 | -36.55 | 89.88 | 88.94 | -26.23 | -86.10 | 2.26 | -0.6134 | 0.7459 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
MoonLake Immunotherapeutics | 0.00 | -54.80m | 3.32bn | 50.00 | -- | 6.28 | -- | -- | -0.9043 | -0.9043 | 0.00 | 8.28 | 0.00 | -- | -- | 0.00 | -11.08 | -- | -11.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Apogee Therapeutics Inc | 0.00 | -118.49m | 3.32bn | 91.00 | -- | 4.16 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Dyne Therapeutics Inc | 0.00 | -257.60m | 3.37bn | 152.00 | -- | 4.33 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
TG Therapeutics Inc | 346.73m | 95.69m | 3.44bn | 300.00 | 36.98 | 19.35 | 35.84 | 9.91 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Avoro Capital Advisor LLCas of 31 Mar 2024 | 5.67m | 7.51% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.52m | 7.31% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 4.32m | 5.73% |
Wellington Management Co. LLPas of 31 Mar 2024 | 3.81m | 5.04% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 2.68m | 3.55% |
Polar Capital LLPas of 31 Mar 2024 | 2.61m | 3.46% |
Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.48m | 3.29% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 2.48m | 3.28% |
Commodore Capital LPas of 31 Mar 2024 | 2.17m | 2.87% |
Adage Capital Management LPas of 31 Mar 2024 | 1.67m | 2.22% |